Register | Login
World Pharma News .net


Finalising a review of the safety and efficacy of dextropropoxyphene-containing medicines, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that their risks, particularly the risk of potentially fatal overdose, are greater than their benefits. The Committee therefore recommended that the marketing authorisations for these medicines be withdrawn across the European Union.

Who Voted for this Story



Enter your email address:

Delivered by FeedBurner